Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener
Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2018-11-15 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $17.22 | -25,000 | 301,352 | -8% | -$430,500 | |||||
| D | 2018-11-12 | EXAS | Exact Sciences Corp | Zanotti Katherine S | Dir | S - Sale+OE | $69.00 | -7,667 | 102,102 | -7% | -$529,023 | |||||
| D | 2018-11-12 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | S - Sale+OE | $69.00 | -163,514 | 976,780 | -14% | -$11,282,466 | |||||
2018-11-12 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale | $134.49 | -1,866 | 10,575 | -15% | -$250,961 | ||||||
2018-11-12 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $40.00 | -2,173 | 5,379,825 | 0% | -$86,920 | ||||||
2018-11-07 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $17.32 | -20,000 | 138,739 | -13% | -$346,400 | ||||||
2018-11-08 | INCY | Incyte Corp | Bienaime Jean Jacques | Dir | P - Purchase | $68.77 | +1,000 | 6,668 | +18% | +$68,765 | ||||||
| D | 2018-11-07 | CRL | Charles River Laboratories International Inc | Johst David P | Corporate EVP | S - Sale+OE | $136.00 | -23,356 | 196,493 | -11% | -$3,176,416 | |||||
| M | 2018-11-05 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale | $75.01 | -38,311 | 41,040 | -48% | -$2,873,633 | |||||
| D | 2018-11-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres, Prod Dev, Med Aff, CMO | S - Sale+OE | $14.16 | -12,000 | 342,793 | -3% | -$169,920 | |||||
2018-11-01 | EXEL | Exelixis, Inc. | Scangos George A | Dir | S - Sale | $14.66 | -25,000 | 1,535,576 | -2% | -$366,400 | ||||||
| D | 2018-11-02 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $17.57 | -37,499 | 318,705 | -11% | -$658,964 | |||||
| M | 2018-10-31 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale | $71.73 | -79,673 | 79,351 | -50% | -$5,714,841 | |||||
2018-10-15 | XON | Intrexon Corp | Liffman Joel D | SVP, Finance | S - Sale | $14.59 | -79,000 | 79,500 | -50% | -$1,152,808 | ||||||
2018-10-08 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale | $69.36 | -58,000 | 159,024 | -27% | -$4,022,933 | ||||||
| D | 2018-10-03 | INCY | Incyte Corp | Trower Paul | Principal Accounting Officer | S - Sale+OE | $70.00 | -10,000 | 14,172 | -41% | -$700,000 | |||||
| D | 2018-10-03 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $70.00 | -10,000 | 32,324 | -24% | -$700,000 | |||||
2018-10-03 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $70.00 | -1,000 | 12,427 | -7% | -$70,000 | ||||||
2018-10-01 | EXEL | Exelixis, Inc. | Scangos George A | Dir | S - Sale | $17.86 | -25,000 | 1,560,576 | -2% | -$446,500 | ||||||
| D | 2018-10-01 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $17.82 | -12,501 | 318,705 | -4% | -$222,768 | |||||
| D | 2018-10-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres, Prod Dev, Med Aff, CMO | S - Sale+OE | $17.77 | -12,000 | 342,793 | -3% | -$213,240 | |||||
| D | 2018-10-01 | EXAS | Exact Sciences Corp | Coward D Scott | Chief Administrative Officer | S - Sale+OE | $79.51 | -2,190 | 79,546 | -3% | -$174,118 | |||||
| M | 2018-09-25 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $58.58 | -132,304 | 9,257,361 | -1% | -$7,750,266 | |||||
| M | 2018-09-25 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $58.58 | -132,304 | 8,895,510 | -1% | -$7,750,266 | |||||
2018-09-24 | EXEL | Exelixis, Inc. | Scangos George A | Dir | S - Sale | $16.85 | -25,000 | 1,585,576 | -2% | -$421,250 | ||||||
| DM | 2018-09-18 | NRC | National Research Corp | Karas Kevin R | SVP Finance, CFO, Treas, Secy | S - Sale+OE | $39.53 | -4,800 | 15,316 | -24% | -$189,738 | |||||
2018-09-21 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $58.47 | -2,713 | 9,389,665 | 0% | -$158,629 | ||||||
2018-09-21 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $58.47 | -2,713 | 9,027,814 | 0% | -$158,629 | ||||||
| M | 2018-09-19 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $59.31 | -114,983 | 9,030,527 | -1% | -$6,819,261 | |||||
| M | 2018-09-19 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $59.31 | -114,983 | 9,392,378 | -1% | -$6,819,138 | |||||
| D | 2018-09-21 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $38.20 | -229 | 0 | -100% | -$8,748 | |||||
| DM | 2018-09-18 | NRC | National Research Corp | Karas Kevin R | SVP Finance, CFO, Treas, Secy | S - Sale+OE | $39.53 | -4,800 | 15,316 | -24% | -$189,738 | |||||
2018-09-18 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $40.00 | -1,451 | 5,381,998 | 0% | -$58,040 | ||||||
| DM | 2018-09-06 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $38.79 | -17,137 | 229 | -99% | -$664,717 | |||||
2018-09-17 | SNMX | Senomyx Inc | Senvest Management, LLC | 10% | S - Sale | $1.48 | -2,689,504 | 3,663,101 | -42% | -$3,967,825 | ||||||
2018-09-14 | BASI | Bioanalytical Systems Inc | Kissinger Peter | 10% | P - Purchase | $1.74 | +10,000 | 1,881,677 | +1% | +$17,382 | ||||||
2018-09-14 | BASI | Bioanalytical Systems Inc | Neff R Matthew | Dir | P - Purchase | $1.66 | +2,500 | 15,000 | +20% | +$4,150 | ||||||
2018-09-14 | PIRS | Pieris Pharmaceuticals, Inc. | Kiritsy Christopher P | Dir | P - Purchase | $5.11 | +5,000 | 10,000 | +100% | +$25,525 | ||||||
2018-09-13 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $126.47 | -413,233 | 134,440 | -75% | -$52,263,088 | ||||||
| DM | 2018-09-12 | SRNE | Sorrento Therapeutics, Inc. | Abg Management Ltd | 10% | S - Sale+OE | $5.02 | -297,568 | 6,791,335 | -4% | -$1,492,723 | |||||
| M | 2018-09-11 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $124.83 | -370,470 | 576,984 | -39% | -$46,244,717 | |||||
2018-09-11 | BASI | Bioanalytical Systems Inc | Downing Philip A | SVP, Preclinical Srvcs. | P - Purchase | $1.67 | +5,000 | 20,765 | +32% | +$8,350 | ||||||
| A | 2018-09-07 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $126.63 | -221,900 | 3,154,267 | -7% | -$28,099,197 | |||||
| D | 2018-09-07 | IQV | Iqvia Holdings Inc. | Knightly Kevin C | See Remarks | S - Sale+OE | $126.46 | -9,216 | 19,323 | -32% | -$1,165,455 | |||||
2018-09-07 | IQV | Iqvia Holdings Inc. | Danhakl John G | Dir | S - Sale | $126.63 | -221,900 | 3,154,267 | -7% | -$28,099,197 | ||||||
| D | 2018-09-04 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $18.53 | -22,500 | 342,793 | -6% | -$416,925 | |||||
| DM | 2018-09-04 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $39.03 | -5,263 | 17,366 | -23% | -$205,400 | |||||
| D | 2018-09-04 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $73.21 | -10,000 | 32,324 | -24% | -$732,100 | |||||
2018-09-04 | CRL | Charles River Laboratories International Inc | Kochevar Deborah Turner | Dir | S - Sale | $123.66 | -4,066 | 6,424 | -39% | -$502,799 | ||||||
2018-08-30 | HPPI | Hedgepath Pharmaceuticals, Inc. | Hasara Garrison J. | CFO, Treasurer | S - Sale | $0.27 | -100,000 | 3,959,044 | -2% | -$27,000 | ||||||
| D | 2018-08-28 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $39.42 | -600 | 22,629 | -3% | -$23,650 | |||||
2018-08-28 | EXAS | Exact Sciences Corp | Wyzga Michael S | Dir | S - Sale | $74.85 | -2,468 | 9,112 | -21% | -$184,730 | ||||||
| M | 2018-08-24 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $40.00 | -14,485 | 5,383,449 | 0% | -$579,400 | |||||
2018-08-27 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $54.75 | -5,224,997 | 0 | -100% | -$286,068,586 | ||||||
| M | 2018-08-22 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.14 | -161,749 | 4,397,934 | -4% | -$6,168,842 | |||||
| D | 2018-08-20 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $17.82 | -90,000 | 318,705 | -22% | -$1,604,216 | |||||
| D | 2018-08-21 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $70.00 | -10,000 | 32,324 | -24% | -$700,000 | |||||
| M | 2018-08-17 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.03 | -38,480 | 5,559,683 | -1% | -$1,463,503 | |||||
| D | 2018-08-15 | EXEL | Exelixis, Inc. | Marchesi Vincent T | Dir | S - Sale+OE | $19.50 | -40,000 | 133,850 | -23% | -$780,000 | |||||
| M | 2018-08-13 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.05 | -41,393 | 5,598,163 | -1% | -$1,574,900 | |||||
| D | 2018-08-13 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $120.06 | -1,249 | 12,441 | -9% | -$149,948 | |||||
| M | 2018-08-09 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -4,364 | 5,639,556 | 0% | -$165,832 | |||||
2018-08-09 | PRAH | Pra Health Sciences, Inc. | Kkr Pra Investors L.P. | 10% | S - Sale | $101.01 | -6,500,000 | 6,695,984 | -49% | -$656,565,000 | ||||||
2018-08-09 | SYNH | Syneos Health, Inc. | Thomas H. Lee Advisors, LLC | 10% | S - Sale | $49.73 | -6,000,000 | 19,252,226 | -24% | -$298,380,000 | ||||||
2018-08-09 | SYNH | Syneos Health, Inc. | Thomas H. Lee Advisors, LLC | 10% | S - Sale | $49.73 | -6,000,000 | 19,252,226 | -24% | -$298,380,000 | ||||||
2018-08-10 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $54.35 | -5,175,000 | 5,224,997 | -50% | -$281,261,250 | ||||||
| DM | 2018-08-07 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $21.04 | -234,267 | 318,705 | -42% | -$4,928,523 | |||||
2018-08-07 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $57.06 | -138,105 | 9,507,361 | -1% | -$7,880,271 | ||||||
2018-08-06 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $20.92 | -2,361 | 158,735 | -1% | -$49,392 | ||||||
| M | 2018-08-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -56,334 | 5,643,920 | -1% | -$2,140,734 | |||||
| A | 2018-08-02 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -7,361 | 5,700,254 | 0% | -$279,718 | |||||
| M | 2018-08-02 | MEDP | Medpace Holdings, Inc. | Troendle August J. | Pres, CEO, 10% | S - Sale | $59.26 | -731,460 | 9,645,466 | -7% | -$43,344,976 | |||||
2018-08-02 | MEDP | Medpace Holdings, Inc. | Geiger Jesse J | CFO, COO, Lab Operations | S - Sale | $60.15 | -7,407 | 0 | -100% | -$445,531 | ||||||
2018-08-02 | IQV | Iqvia Holdings Inc. | Parks Robert | SVP, Controller | S - Sale | $124.34 | -871 | 1,195 | -42% | -$108,304 | ||||||
| D | 2018-08-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $20.56 | -22,500 | 292,793 | -7% | -$462,600 | |||||
| M | 2018-07-31 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -12,490 | 5,703,520 | 0% | -$474,644 | |||||
2018-07-30 | EXAS | Exact Sciences Corp | Zanotti Katherine S | Dir | S - Sale | $58.86 | -2,847 | 106,197 | -3% | -$167,574 | ||||||
2018-07-30 | EXAS | Exact Sciences Corp | Fallon John A. | Dir | S - Sale | $58.86 | -2,373 | 33,767 | -7% | -$139,675 | ||||||
2018-07-30 | EXAS | Exact Sciences Corp | Doyle James Edward | Dir | S - Sale | $58.86 | -1,318 | 37,093 | -3% | -$77,577 | ||||||
2018-07-30 | EXAS | Exact Sciences Corp | Carey Thomas D. | Dir | S - Sale | $58.86 | -3,427 | 48,983 | -7% | -$201,713 | ||||||
| D | 2018-07-30 | EXAS | Exact Sciences Corp | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $57.78 | -8,984 | 33,237 | -21% | -$519,096 | |||||
| D | 2018-07-26 | IQV | Iqvia Holdings Inc. | Bousbib Ari | See Remarks | S - Sale+OE | $122.09 | -368,640 | 1,331,519 | -22% | -$45,007,258 | |||||
| D | 2018-07-26 | IQV | Iqvia Holdings Inc. | Rittenmeyer Ronald A | Dir | S - Sale+OE | $122.41 | -7,680 | 59,307 | -11% | -$940,109 | |||||
| D | 2018-07-24 | CRL | Charles River Laboratories International Inc | Molho Davide | Pres, COO | S - Sale+OE | $125.00 | -18,773 | 57,903 | -24% | -$2,346,625 | |||||
2018-07-23 | CRL | Charles River Laboratories International Inc | Molho Davide | Pres, COO | S - Sale | $125.00 | -11,600 | 62,827 | -16% | -$1,450,000 | ||||||
| D | 2018-07-18 | XON | Intrexon Corp | Sabzevari Helen | Pres, Precigen, Inc. | S - Sale+OE | $14.54 | -8,402 | 16,598 | -34% | -$122,165 | |||||
| D | 2018-07-17 | CRL | Charles River Laboratories International Inc | Molho Davide | Pres, COO | S - Sale+OE | $120.00 | -11,126 | 74,427 | -13% | -$1,335,120 | |||||
| D | 2018-07-16 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale+OE | $3.40 | -39,497 | 2,164,330 | -2% | -$134,290 | |||||
2018-07-17 | CRL | Charles River Laboratories International Inc | Girshick Birgit | Corporate EVP | S - Sale | $119.90 | -3,978 | 18,999 | -17% | -$476,962 | ||||||
| D | 2018-07-16 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $21.13 | -90,000 | 318,705 | -22% | -$1,901,700 | |||||
| AM | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
| M | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
2018-07-09 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -8,955 | 2,044,730 | 0% | -$30,447 | ||||||
| D | 2018-07-09 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $71.11 | -10,000 | 32,963 | -23% | -$711,100 | |||||
2018-07-09 | INCY | Incyte Corp | Iyengar Vijay K | EVP GPS, BD, Licensing | S - Sale | $71.34 | -606 | 8,103 | -7% | -$43,232 | ||||||
| M | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
2018-07-03 | XON | Intrexon Corp | Kirk Randal J | CEO, 10% | P - Purchase | $13.37 | +7,479,431 | 66,789,237 | +13% | +$99,999,992 | ||||||
| M | 2018-07-03 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -7,719 | 5,723,004 | 0% | -$293,347 | |||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.55 | -2,775 | 322,178 | -1% | -$309,540 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.34 | -5,348 | 274,451 | -2% | -$595,462 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |